Skip to content

Safety evaluation

Safety evaluation of excessive intake of supplements for healthy adults - Safety evaluation of excessive intake of supplements for healthy adults

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000044645
Enrollment
15
Registered
2022-08-20
Start date
2021-06-25
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adult

Interventions

Intake of the supplement, 5-fold quantity of recommended daily intake, for 4 weeks

Sponsors

EP Mediate Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Healthy males and females from 20 to 64 years old

Exclusion criteria

Exclusion criteria: (1) Subjects who are judged as unsuitable for the study based on the results of the lifestyle questionnaire (2) Subjects who constantly use health foods richly containing the involvement ingredients (3) Subjects having a disease requiring treatments or a history of serious diseases for which medication was required (4) Subjects having possibilities for emerging allergy related to the study (5) Subjects who are judged as unsuitable for the study based on the results of clinical and physical examination before the study (6) Subjects who had participated in other clinical studies within one month before the study or are planned to participate in other clinical studies after informed consent for the study (7) Subjects who intend to become pregnant or lactating during the test period (8) Subjects judged as unsuitable for the study by the principle investigator for other reasons

Design outcomes

Primary

MeasureTime frame
Hematologic test, Biochemical test, Urine test, Blood pressure/pulsation, Weight/body mass index, Medical Interview, before the study and at weeks 2 and 4 after using the test food. Adverse events thorough the study

Countries

Japan

Contacts

Public ContactKei Yasui

EP Mediate Co., Ltd. Development Business Headquarters, TTC Center, Trial Planning Department

yasui475@eps.co.jp03-5657-4983

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026